Home PipelineTebotelimab (PD-1 × LAG-3)

Background

Tebotelimab (previously known as MGD013) is an investigational, bispecific DART® molecule designed to independently or coordinately block PD-1 and LAG-3 checkpoint molecules to sustain or restore the function of exhausted T cells for the treatment of cancer. Monoclonal antibodies that target the immune checkpoints Lymphocyte-activation gene 3 (LAG-3) and PD-1 may have enhanced clinical activity when given in combination. Tebotelimab has been engineered to bind PD-1 and LAG-3 concomitantly or independently and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function.

Clinical Development

Tebotelimab is currently being studied in combination with enoblituzumab (an investigational monoclonal antibody that targets B7-H3) in patients with squamous cell carcinoma of the head and neck who are PD-L1 negative.

Our Rights

Zai Lab has development and commercialization rights in Greater China. MacroGenics retains full development and commercialization rights in all other territories.

Clinical Trials

Presentations & Publications

Relevant Publications and Presentations can be found at https://dev.macrogenics.com/publications/.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close